An Open-Label, Multicenter Extension Study Providing Continued Access to Treatment in Patients with a Neurological Disease Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Study and without Access to A Post Trial Access Program

Status

Withdrawn

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-507633-21-00

Acronym

MN45053

Enrollment

196

Registered

2024-04-23

Start date

Unknown

Completion date

Unknown

Last updated

2024-04-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neurological Disease

Brief summary

Not available

Interventions

DRUGOcrelizumab

DRUG-

DRUGMETHYLPREDNISOLONE

DRUGDEXAMETHASONE

DRUGOcrevus

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Not available	—

Countries

Czechia, France, Germany

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026